{"filing":{"accession_number":"0001193125-26-271137","cik":"0001782223","ticker":"PYXS","company_name":"Pyxis Oncology, Inc.","form":"8-K","filing_date":"2026-06-15","report_date":null,"primary_document":"pyxs-20260615.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1782223/000119312526271137/pyxs-20260615.htm"},"events":[{"id":11074,"run_id":9710,"accession_number":"0001193125-26-271137","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder vote results from Pyxis Oncology's Annual Meeting of Stockholders held on June 15, 2026. The filing reports the final voting tallies for two proposals: (1) election of three Class II directors (Thomas Civik, Freda Lewis-Hall, and Michael A. Metzger) and (2) ratification of Ernst \u0026 Young LLP as independent auditor. The detailed vote counts (For, Against/Withheld, Abstain, and Broker Non-Votes) are provided for each proposal, which is the hallmark of Item 5.07 shareholder vote results disclosures.","company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","filing_date":"2026-06-15","form":"8-K","submitted_at":null,"items":[{"id":7570,"accession_number":"0001193125-26-271137","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from Pyxis Oncology's Annual Meeting of Stockholders held on June 15, 2026. The filing reports the final voting tallies for two proposals: (1) election of three Class II directors (Thomas Civik, Freda Lewis-Hall, and Michael A. Metzger) and (2) ratification of Ernst \u0026 Young LLP as independent auditor. The detailed vote counts (For, Against/Withheld, Abstain, and Broker Non-Votes) are provided for each proposal, which is the hallmark of Item 5.07 shareholder vote results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:23:32.313527+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7570,"accession_number":"0001193125-26-271137","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from Pyxis Oncology's Annual Meeting of Stockholders held on June 15, 2026. The filing reports the final voting tallies for two proposals: (1) election of three Class II directors (Thomas Civik, Freda Lewis-Hall, and Michael A. Metzger) and (2) ratification of Ernst \u0026 Young LLP as independent auditor. The detailed vote counts (For, Against/Withheld, Abstain, and Broker Non-Votes) are provided for each proposal, which is the hallmark of Item 5.07 shareholder vote results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:23:32.313527+00:00","company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","filing_date":"2026-06-15"}]}